drugset / Trial / NCT04839042
A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers
Non-randomizedSequentialOpen-labelPrevention
Summary
This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via the intramuscular (IM), intranasal (IN) or inhaled (IH) route in healthy volunteers.
Timeline
- Start
- 2021-06-28
- Primary completion
- 2025-03-04
- Completion
- 2025-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SC-Ad6-1 | Vaccine | — | Intramuscular |